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Introduction
Tuberculosis is a common problem, especially in the 
developing world. In 2010, the World Health Organization 
estimated 8.8 million new cases worldwide.1 South Africa 
is one of the epicentres of the epidemic, with an incidence 
of 971 per 100 000. This means that almost one per cent 
of the population develops tuberculosis every year. Fifteen 
per cent of these are children and two thirds will be co-
infected with human immunodeficiency virus (HIV). Even in 
the developed world, concerns have been raised about the 
impact of immigration on the transmission of tuberculosis.2 
There has been a marked increase in the number of 
tuberculosis cases, which has paralleled the emergence 
of HIV. This increase can be explained by the fact that the 
lifetime risk of an immunocompetent patient who is infected 
with tuberculosis, progressing to develop active disease, is 
10%. This rises to 5-8% per year in a patient with HIV.3
Despite high cure rates obtained by following a full six-
month course of antibiotic therapy, the problem of resistance 
is starting to emerge. 1.8% of new cases and 6.7% of 
retreatment cases in South Africa are multi-drug resistant 
(MDR), defined as resistance to rifampicin and isoniazid.4 In 
2009, almost 600 cases of extensively drug-resistant (XDR) 
tuberculosis were diagnosed. By definition, XDR tuberculosis 
possesses additional resistance to a fluroquinolone and any 
second-line injectable drugs, e.g. amikacin. Most cases of 
MDR tuberculosis and XDR tuberculosis in South Africa have 
been detected in the Western Cape, the Eastern Cape and 
KwaZulu-Natal (Table I).5
Table I: The incidence of multidrug-resistant and extensively 
drug-resistant tuberculosis by province in 20095
Province Number of cases of 
multidrug-resistant 
tuberculosis
Number of cases of 
extensively drug-
resistant tuberculosis
Eastern Cape 1 858 123
Free State 253 3
Gauteng 1 307 65
KwaZulu-Natal 1 773 254
Limpopo 204 6
Mpulmalanga 446 18
North West 520 13
Northern Cape 631 40
Western Cape 2 078 72
As anaesthetists, we will certainly be faced with this disease 
and the associated implications for patient health, as well as 
the potential for drug-drug interactions. 
Pathophysiology
Mycobacterium tuberculosis is spread via the airborne 
transmission of small droplets (0.5-5 μm). Usually, infection 
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occurs between household contacts with prolonged 
contact. However, exposure to only a few bacteria is 
needed to establish infection. Because of its high oxygen 
tension, the primary site of infection is the upper lobe 
of the lung, forming the Ghon focus. Bacteria invade 
and replicate within macrophages. This is followed by a 
T cell-mediated response, which walls off the infected cells 
to form a granuloma. Bacteria within the granuloma can 
become dormant, resulting in latent infection. At this stage, 
the patient will be asymptomatic, but may show a positive 
response to a tuberculin skin test.6 
Factors that increase the likelihood of progression to active 
disease include time from exposure (most common in the 
first year), the age of the patient (younger than five years 
old), and the competency of the immune system.7
Patients may present in a number of ways: 
•	 Pulmonary disease is the most common presentation, 
with a chronic productive cough and haemoptysis. 
Enlargement of the lymph nodes can cause 
bronchial compression with localised wheeze, while 
haematogenous spread can lead to widespread lung 
infection, known as miliary tuberculosis. 
•	 Constitutional symptoms secondary to the production of 
proinflammatory cytokines are commonly seen. These 
include fever, night sweats, loss of weight, or failure to 
thrive in children.
•	 Hypersensitivity phenomena may occur following 
activation of T cell-mediated immunity. These include 
conditions such as erythema nodosum, phlyctenular 
conjunctivitis and Poncet’s disease. 
•	 Extrapulmonary disease can manifest as infection 
of almost any organ. Common examples include 
lymphadenitis (scrofula), bones and joints, abdominal 
tuberculosis and meningitis.8
Diagnosis
Traditionally, diagnosis is made by visualising acid-fast 
bacilli on sputum. Newer technology, such as the Xpert® M. 
tuberculosis/resistance to rifampicin or GeneXpert®, make 
use of real-time polymerase chain reaction to detect specific 
DNA sequences. They can provide much quicker results 
(within two hours), as well as information on rifampicin 
resistance.9
Obtaining a sputum sample can be difficult in children, and 
the diagnosis is usually made on the basis of signs and 
symptoms of tuberculosis, positive contact and a positive 
tuberculin skin test (Mantoux®).8 Gastric aspirates can be 
used, but have a pick-up rate of less than 40%.10 T cell 
interferon-γ (IFN-γ) release assays, which measure the 
number of IFN-γ-secreting T cells, have been developed 
as an alternative immune-based approach to the tuberculin 
skin test to detect infection.11
Treatment
The cornerstone of treatment is directly observed treatment 
(DOT) for at least six months. First-line treatment includes 
rifampicin, isoniazid (INH), ethambutol and pyrazinamide, 
given according to guidelines for new cases, retreatment, 
and children younger than eight years of age.12 Fixed-dose 
combinations help to reduce the pill burden. Steroids are 
given for six weeks in cases of tuberculosis meningitis, 
pericarditis and airway obstruction from lymph node 
compression.7
Tuberculosis treatment has the potential for serious side-
effects, some of which may impact on the anaesthetist. 
Rifampicin can cause thrombocytopaenia when given in 
high doses. INH may cause sensory neuropathy, which 
should be ascertained clinically before performing regional 
nerve blocks. This complication can be prevented by adding 
pyridoxine (vitamin B6) in high-risk cases. Ethambutol has 
the potential to cause optic neuritis. For this reason, it is not 
routinely given to children. 
Drug-induced hepatitis is a worrying complication. When 
tuberculosis treatment is combined with concomitant 
antiretroviral therapy, a mild elevation in liver enzymes is 
common. However, symptomatic hepatitis has a mortality of 
almost 5%,13 and requires immediate halting of tuberculosis 
drugs, with careful re-introduction under specialist care. 
Wherever possible, surgery should be avoided during this 
period.
MDR and XDR tuberculosis require extended treatment 
for up to two years with four or five drugs, depending on 
resistance patterns. Besides the added cost of treatment, 
there is also an increased risk of life-threatening side-effects. 
Anaesthetic implications
The anaesthetist may be presented with a patient with 
tuberculosis in a number of scenarios. Procedures such as 
lymph node biopsies and bronchoscopies may be required 
to obtain a definitive diagnosis. Patients may require surgery 
for tuberculosis complications, such as hydrocephalus and 
intestinal obstruction. Lastly, patients requiring elective 
or emergency surgery may have active tuberculosis 
incidentally, or be on antituberculous therapy.
There are three major implications for the anaethetist:
•	 The general state of the patient’s health and the impact 
of the disease on organ function. 
•	 The treatment that the patient is receiving and the 
considerable potential for drug interactions. 
•	 The risk of transmission of tuberculosis to staff and other 
patients.
Patient assessment
The patient may be acutely ill, either with tuberculosis 
or a superadded infection. Alternately, he or she may be 
Review Article: Tuberculosis: the implications for anaesthesia
303 2013;19(6)South Afr J Anaesth Analg
chronically ill, malnourished and frequently anaemic. 
Chronic lung disease with bronchiectasis and fibrosis 
develops as a result of long-standing tuberculosis. A full 
history, examination and relevant investigations are needed, 
as dictated by the clinical condition of the patient, to 
determine the extent of organ dysfunction. 
Drug interactions
Drugs used for the treatment of tuberculosis probably have 
the greatest impact on the anaesthetist. Drug interactions 
are mostly due to pharmacokinetic changes following the 
induction of liver enzymes. Rifampicin is responsible for 
most observed drug interactions. It is a potent inducer of 
the cytochrome P450 system, especially isoenzyme 3A4, 
which is involved in the metabolism of nearly 50% of drugs. 
This can result in increased metabolism, and therefore 
subtherapeutic effects, or the increased production of toxic 
metabolites. CYP3A4 is also found in the small intestine. For 
this reason, oral drugs are more affected than those given 
intravenously. On the other hand, INH is a CYP450 inhibitor. 
However, due to differential effect on specific isoenzymes, 
these two drugs do not simply cancel each other out. The 
potential for a drug interaction is further compounded 
when a patient is also taking antiretroviral treatment, and 
specifically protease inhibitors.
The extent of this problem was demonstrated by Backman, 
Olkkola and Neuvonen.14 Oral midazolam was given to 
healthy volunteers following five days of pretreatment 
with either rifampicin or placebo. They showed a 96% 
reduction in area-under-concentration time curve and a 
94% reduction in maximum concentration in the rifampicin 
group. They concluded that “orally administered midazolam 
is ineffective during rifampin treatment”. This has obvious 
implications for the use of oral midazolam as anxiolytic 
premedication in patients on antituberculous therapy. 
Swart and Harris reviewed the effects of antituberculous 
therapy on a number of drugs and is an excellent reference.15 
This article will focus only on those drugs that relate to 
anaesthesia. Few studies have been conducted specifically 
that have examined anaesthetic agents and tuberculosis 
therapy. Most available information is deduced from studies 
with other known enzyme inducers or inhibitors. 
Induction agents
Recovery from the effect of intravenous induction agents 
is primarily due to redistribution. TB therapy is unlikely 
to have an effect on a single induction dose. However 
increased metabolism may be important in total intravenous 
anaesthesia, with a greater potential for awareness. While 
there is no evidence to support this, one should be mindful 
of this risk and consider the use of depth of anaesthesia 
monitoring in these patients. 
Local Anaesthetics
As they exert their action primarily at the site of injection, 
local anaesthetic drugs are still likely to be effective, and 
help to avoid many of the other drug interactions seen with 
opiates. Increased metabolism may result in a decreased 
risk of local anaesthetic toxicity.
Volatile anaesthetics
Halothane is metabolised via isoenzyme CYP2E1 to trifluro-
acetic acid. This molecule has the potential to act as a 
hapten to trigger an immune mediated hepatitis.  CYP2E1 is 
induced by INH. Thus patients on antituberculous therapy 
are potentially at increased risk of halothane hepatitis.16 The 
minimal metabolism of the newer volatile agents makes 
them a better choice. 
Neuromuscluar blocking drugs
Unless liver dysfunction results in decreased pseudo-
cholinesterase levels, the effect of suxamethomium is 
unchanged. Similarly cisatracurium (organ independent 
metabolism) and pancuronium (renal excretion) are minimally 
affected by tuberculosis therapy. While no trials specifically 
look at interactions with TB treatment, it has been shown 
that the effect of vecuronium is prolonged by cimetidine, 
an enzyme inhibitor, and shortened by phenytoin enzyme 
induction.17 Rocuronium is less affected but resistance to 
muscle blockade has been shown with carbamazepine.18 
Streptomycin may potentiate the effects of non-depolarising 
agents. Non-depolarising neuromuscular blocking drugs 
should, therefore, be titrated to response, with frequent 
evaluation using a nerve stimulator. 
Analgesics
While the metabolism of morphine predominantly involves 
phase II reactions via UDP-glucuronosyltransferases, 
antituberculous therapy seems to have an effect. A loss of 
analgesic effect of oral morphine has been demonstrated 
following pretreatment with rifampicin.19 Fentanyl and 
alfentanil are both extensively metabolised by CYP450 3A4, 
therefore, also show the potential for a shortened duration 
of action. 
The metabolism of codeine is interesting. The analgesic 
effect of codeine is mediated through its metabolism to 
morphine via CYP450 2D6. One may, therefore, expect 
a greater analgesic effect following enzyme induction. 
However, it is also metabolised to inactive norcodeine via 
isoenzyme 3A4, resulting in an overall decreased effect.15 
The effect of tramadol is unchanged.  
Of the non-steroidal anti-inflammatory drugs, the effect 
of diclofenac is decreased with rifampicin, while that of 
ibuprofen is unchanged, making it a safer option.15 Analgesia 
should therefore be titrated to effect with the potential to 
require more frequent dosing. 
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Table II details the effect of tuberculosis treatment on 
various anaesthestic agents.
Therefore, the choice of anaesthetic depends on the patient, 
the procedure and the severity of the disease. Regional 
anaesthesia is often preferred in patients with chronic lung 
disease and to avoid potential drug interactions. However, 
this is not possible in many cases. Drugs should be tailored 
to the expected drug interaction and monitored for effect. 
Hepatotoxic drugs must be avoided. 
Spread of tuberculosis
The spread of tuberculosis to other patients (many of whom 
are immunocompromised) and to theatre staff is an area 
of concern. Because of the close proximity of the patient’s 
airway during intubation, anaesthetists are at particular 
risk.20 Children are less likely to have cavitary disease and 
are, therefore, less infectious.7 
In 2005, the American Society of Anesthesiologists 
(ASA) produced guidelines relating to the perioperative 
management of patients with active tuberculosis.21 Elective 
surgery should be delayed until the patient is no longer 
infectious. The ASA defines this as having been on treatment 
for 2-3 weeks, clinically getting better, and having had three 
negative sputa on different days. While practically, the third 
criterion might be difficult to achieve, the first two should 
certainly be followed. 
Elective cases should be booked as the last case of the day 
to allow decontamination of the theatre following the case. 
The patient should be transferred wearing an N95® mask. 
He or she should be brought straight to theatre, rather 
than wait in a central holding area where exposure to other 
patients could occur. Traffic inside the theatre should be 
minimised to essential staff. Theatre staff must wear N95® 
masks. This is especially true for high-risk procedures, such 
as intubation and bronchoscopy. The anaesthetist should 
ensure adequate anaesthesia and muscle relaxation to 
ensure that the patient does not cough on intubation. 
Unless gas flows are stopped for longer than one hour 
between cases, M. tuberculosis has been shown to be able 
to pass through the anaesthetic machine.22 The presence 
of a soda lime canister does not guarantee eradication, as 
desiccated soda lime is not bactericidal. Therefore, it is 
recommended that a bacterial filter is placed both by the 
patient’s airway and on the expiratory limb of the circuit. 
These should be able to filter more than 99.97% of particles 
greater than 0.3 μm. While not specifically advocated by 
ASA, it would be good practice to sterilise the circuits after 
such a case. 
Ideally, the patients should be recovered in a private room, 
rather than in the central recovery area. Practically, this may 
mean that he or she will need to recover in theatre before 
going back to the ward directly. The N95® mask should be 
placed back on as soon as active airway management is no 
longer required. However, these masks increase airway flow 
resistance by approximately 120%.23 A large venture-type 
face mask can be placed over the N95® mask to provide 
supplemental oxygenation. The N95® should not be worn by 
the patient if he or she is hypoxic or in respiratory distress. 
Similary, if hypoxia or respiratory distress occurs while 
wearing the mask, it should be removed. 
Skin testing programmes for at-risk staff have been 
advocated by ASA, as well as in the most recent National 
Institute for Clinical Excellence guidelines.24 Staff members 
who receive a positive tuberculin skin test are prescribed 
INH for 6-9 months. This has been shown to prevent 
progression to active disease.25 The confounding effects of 
previous BCG immunisation and poor compliance with INH 
therapy hampers these programmes. 
Table II: A summary of the effect of tuberculosis treatment on 
various anaesthetic agents
Drug class Effect of tuberculosis 
treatment
Recommendation




Volatile agents An increased risk of 
halothane hepatitis




Unchanged Useful to avoid general 
anaesthetic and 
opioids
Muscle relaxants Increased metabolism 
of rocuronium and 
vecuronium
Titrate and monitor 
response using nerve 
stimulator
Opiates Increased metabolism, 
often requiring more 
frequent dosing
Titrate to effect





Figure I: Example of an N95® mask
Review Article: Tuberculosis: the implications for anaesthesia
305 2013;19(6)South Afr J Anaesth Analg
Conclusion
Tuberculosis is a common problem, especially with the rise 
of HIV. It has significant implications for the anaesthetist. 
The potential for drug interactions is most concerning. The 
transmission of tuberculosis to other patients, theatre staff 
and anaesthesiologists is a potential danger, and active 
measures should be taken to prevent this.
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